Peroxisome proliferator-activated receptor γ agonists: Potential use for treating chronic inflammatory diseases

Arthritis and Rheumatism

Volumn 46, Issue 3, 2002, Pages 598-605

  Oates, James C ^a,b   Reilly, Christopher M ^a   Crosby, Michelle B ^a   Gilkeson, Gary S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FARGLITAZAR; LIGAND; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SB 213068; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; HUMANS; INFLAMMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036185124     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10052     Document Type: Review

References (66)

1. Peroxisome proliferator-activated receptor γ (PPARγ) activation in naive mouse T cells induces cell death
2. PPARγ-mediated regulation of normal and malignant B lineage cells
3. Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation
4. Activation of proliferator-activated receptors α and γinduces apoptosis of human monocyte-derived macrophages
5. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
6. 2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways
7. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
8. Peroxisome proliferator-activated receptors, orphans with ligands and functions
9. PPARγ3 mRNA a distinct PPARγ mRNA subtype transcribed from an independent promoter
10. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
11. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators
12. Inhibition of adipogenesis through map kinase-mediated phosphorylation of PPARγ
13. Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARγ2 in 3T3-L1 cells
14. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding
15. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription
16. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ
17. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
18. PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes
19. Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptor γactivation stimulates expression of the CAP gene
20. Hypertension and insulin resistance: Role of peroxisome proliferator-activated receptor γ
21. Altered gene expression for tumor necrosis factor a and its receptors during drug and dietary modulation of insulin resistance
22. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
23. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
24. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
25. Molecular cloning and characterization of the rat inducible nitric oxide synthase (iNOS) gene
26. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor κB-binding sites
27. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor α expression in neonatal rat cardiac myocytes
28. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene
29. Nuclear receptor coactivators
30. The coregulator exchange in transcriptional functions of nuclear receptors
31. 2 is a ligand for the adipocyte determination factor PPARγ
32. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
33. 2
34. 2 inhibits multiple steps in the NF-κB signaling pathway
35. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
36. The role of PPARγ in macrophage differentiation and cholesterol uptake
37. The PPARs: From orphan receptors to drug discovery
38. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation
39. PPARγ agonists inhibit production of monocyte inflammatory cytokines
40. Interleukin-4-dependent production of PPARγ ligands in macrophages by 12/15-lipoxygenase
41. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
42. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor γ
43. 2 inhibition of mesangial cell iNOS expression
44. 2 in activated murine macrophages
45. 2 and proliferator activation receptor γ agonists
46. Peroxisome proliferator-activated receptor α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
47. 2 and aminoguanidine: A role for peroxisome proliferator-activated receptor γ activation and iNOS expression
48. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
49. Activation of PPAR α or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
50. 2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression
51. Feedback control of cyclooxygenase-2 expression through PPARγ
52. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
53. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists: PPARγ co-association with transcription factor NFAT
54. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2: Evidence for involvement of activator protein-1 and CREB-binding protein/p300
55. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
56. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
57. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor γ inhibit keratinocyte proliferation
58. The organization, promoter analysis, and expression of the human PPARγ gene
59. A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response
60. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
61. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
62. Peroxisome proliferator-activated receptor γ: A versatile metabolic regulator
63. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
64. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
65. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor γ agonists through induction of apoptosis
66. Medical significance of peroxisome proliferator-activated receptors